Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AVIR 
Atea Pharmaceuticals Inc (AVIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AVIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.22% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.18M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 3 | Beta 0.22 | 52 Weeks Range 2.46 - 4.02 | Updated Date 10/15/2025 |
52 Weeks Range 2.46 - 4.02 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.16% | Return on Equity (TTM) -32.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -154678701 | Price to Sales(TTM) 1.9 |
Enterprise Value -154678701 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 79357553 | Shares Floating 60149851 |
Shares Outstanding 79357553 | Shares Floating 60149851 | ||
Percent Insiders 12.72 | Percent Institutions 71.9 |
Upturn AI SWOT
Atea Pharmaceuticals Inc
Company Overview
History and Background
Atea Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat life-threatening viral diseases. Founded in 2014, Atea has focused on developing oral direct-acting antiviral agents for serious viral infections. Atea Pharmaceuticals, Inc. went public in 2020.
Core Business Areas
- Antiviral Drug Development: Focused on developing oral direct-acting antiviral agents for serious viral infections, including COVID-19 and dengue fever.
Leadership and Structure
The leadership team includes Jean-Pierre Sommadossi, PhD, Chief Executive Officer, and Janet Hammond, MD, PhD, Chief Medical Officer. The company operates with a focus on research and development of antiviral therapeutics.
Top Products and Market Share
Key Offerings
- AT-527 (COVID-19 antiviral): AT-527 was an oral antiviral candidate for the treatment of COVID-19. However, clinical trials did not demonstrate sufficient efficacy to continue development. Competitors include Pfizer (Paxlovid - PFE) and Merck (Molnupiravir - MRK).
- AT-752 (Dengue Fever antiviral): AT-752 is another oral antiviral candidate in preclinical development for the treatment of Dengue Fever. Competitors include Takeda (TAK) with Qdenga.
Market Dynamics
Industry Overview
The antiviral drug market is experiencing significant growth due to emerging viral threats and increasing demand for effective treatments. The market is driven by outbreaks, technological advancements, and increasing investment in R&D.
Positioning
Atea Pharmaceuticals aims to be a leader in the development of oral antiviral therapies. Previously focused on Covid and now primarily on dengue fever and other viral illnesses. Competitors have significant market share lead.
Total Addressable Market (TAM)
The global antiviral drugs market is projected to reach billions of dollars. Atea's positioning depends on the success of its antiviral candidates, it's currently positioned in a growth phase but needs to produce a successful drug to capture significant market share.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Focus on oral antiviral therapies
- Proprietary technology platform
Weaknesses
- Reliance on pipeline success
- Limited commercialized products
- Dependence on funding for R&D
Opportunities
- Growing antiviral drug market
- Potential for strategic partnerships
- Expansion into new viral disease areas
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- PFE
- MRK
- TAK
Competitive Landscape
Atea Pharmaceuticals faces intense competition from established pharmaceutical companies with greater resources and commercialized products. Atea Pharmaceuticals has a disadvantage compared to its competitors.
Growth Trajectory and Initiatives
Historical Growth: Atea's growth has been focused on R&D, with significant expenses related to clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals for its drug candidates.
Recent Initiatives: Recent initiatives include advancing the development of AT-752 for Dengue Fever and exploring opportunities for additional antiviral programs.
Summary
Atea Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on developing antiviral therapies. Its future depends heavily on the success of its pipeline candidates, particularly AT-752. The company faces significant competition and regulatory hurdles, but opportunities exist in the growing antiviral drug market. Atea Pharmaceuticals must strategically manage its resources and secure partnerships to maximize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Press Releases
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence. Market share estimates are approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://ateapharma.com |
Full time employees 56 | Website https://ateapharma.com | ||
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.